LCM
VRDN icon

Legato Capital Management’s Viridian Therapeutics VRDN Stock Holding History

Legato Capital Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$414K Sell
21,159
-1,655
-7% -$49.2K 0.04% 567
2025
Q4 		$710K Buy
22,814
+13,018
+133% +$357K 0.06% 451
2025
Q3 		$211K Buy
+9,796
New +$177K 0.02% 512

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Legato Capital Management's VRDN Position: Q1 2026 in Review

Legato Capital Management reduced its Viridian Therapeutics (VRDN) stake by 7.3% in Q1 2026, selling an estimated $49.2K and leaving 21,159 shares worth $414K. The position accounts for 0.04% of the portfolio, ranked #567.

Legato Capital Management first reported a position in VRDN in Q3 2025 and has held it in 3 quarters since. The position peaked at $710K in Q4 2025. 225 funds tracked by Wall St. Rank hold VRDN as of Q1 2026.

  • Legato Capital Management held 21,159 shares of Viridian Therapeutics worth $414K as of Q1 2026.
  • Legato Capital Management sold 1,655 Viridian Therapeutics shares in Q1 2026, an estimated $49.2K.
  • Viridian Therapeutics made up 0.04% of Legato Capital Management's portfolio in Q1 2026, its #567 holding.
  • Legato Capital Management first reported a position in Viridian Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Legato Capital Management's Viridian Therapeutics position peaked at $710K in Q4 2025.
  • 225 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q1 2026.

Based on Legato Capital Management's 13F filing for Q1 2026, filed 14 May 2026.